BACKGROUND:

Copeptin is a novel biomarker that has demonstrated good diagnostic performance in the early diagnosis of patients with acute coronary syndrome; however, its prognostic performance in the short-term survival (28 days) has not been established.

OBJECTIVE:

To determine the prognostic performance of copeptin for 28 day-mortality in patients with acute coronary syndrome.

MATERIAL AND METHOD:

A prospective, observational cohort of patients with acute coronary syndrome was done from January 1st 2014 to November 30 2015, measuring copeptin at presentation, registering deaths and event-free survivors over 28 days.

RESULTS:

Thirty-four patients were included, stratified as having low risk of death if copeptin was ≤ 12 pmol/L, intermediate risk between 12.1 and 32.5 pmol/L, and high risk ≥ 32.5 pmol/L, with a mortality of 0%, 15% and 30%, respectively; hazard ratio between high and low adjusted to confuse factors of 15.9 (CI95% 1.3-190; p = 0.02, Cox multivariable regression model).

CONCLUSION:

Elevated concentrations of copeptin are directly proportional to a higher risk of all-cause mortality, hence it could be used as a prognostic marker.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )